HFSA/ACC/AHA, et al, (Accessed April 1, 2020), cited as Ref 23 in DOI: 10.1007/s11886-020-01293-2 (Q11017)

From Wikibase.slis.ua.edu

Jump to navigation Jump to search

Cited in: "Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty" Curr Cardiol Rep; 2020 04 29 ; 22 (5) 34.

Language	Label	Description	Also known as
English	HFSA/ACC/AHA, et al, (Accessed April 1, 2020), cited as Ref 23 in DOI: 10.1007/s11886-020-01293-2	Cited in: "Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty" Curr Cardiol Rep; 2020 04 29 ; 22 (5) 34.

Statements

Bibliography Entry in a Publication

0 references

Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty (DOI: 10.1007/s11886-020-01293-2)

0 references

HFSA/ACC/AHA Joint Statement addressing concerns re: using RAAS antagonists in COVID-19. (English)

0 references

Publication Date

2020

0 references

First Author string

HFSA/ACC/AHA

0 references

publication URL

https://www.hfsa.org/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician/

0 references

Sitelinks

⧼wikibase-sitelinks-sliswiki⧽(1 entry)

sliswiki HFSA/ACC/AHA, et al, (Accessed April 1, 2020), cited as Ref 23 in DOI: 10.1007/s11886-020-01293-2

Retrieved from "http://wikibase.slis.ua.edu/w/index.php?title=Item:Q11017&oldid=221998"